Recent progress in the discovery and development of negative allosteric modulators of mGluR5

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 4, 2009, Pages 446-457

  Lindsley, Craig W ^a   Emmitte, Kyle A ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Anxiety; Fragile X syndrome; Gastroesophageal reflux disease; Metabotropic glutamate receptor; MPEP; MTEP; Negative allosteric modulator; Pain; Partial antagonist

Indexed keywords

2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 AMINOBUTYRIC ACID A RECEPTOR; ADX 10059; ALCOHOL; AZD 2066; AZD 2516; BENZODIAZEPINE DERIVATIVE; COCAINE; CYTOCHROME P450; FENOBAM; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NAPHTHYRIDINE DERIVATIVE; NPL 2009; PARTIAL AGONIST; PHENYLETHYNYL[1,2,4]METHYLTRIAZINE; PHENYLETHYNYLPYRROLO[1 ,2 A]PYRAZINE; PLACEBO; PROTON PUMP INHIBITOR; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANXIETY; ANXIETY DISORDER; BABOON; BINGE EATING DISORDER; CLINICAL TRIAL; DIABETIC NEUROPATHY; DOG; DRUG DESIGN; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; ENZYME INHIBITION; FRAGILE X SYNDROME; GASTROESOPHAGEAL REFLUX; HUMAN; LOCOMOTION; MIGRAINE; MOUSE; NERVE CELL LESION; NEUROPHARMACOLOGY; NONHUMAN; OSTEOARTHRITIS; PARKINSON DISEASE; REVIEW; REWARD; SINGLE DRUG DOSE; SPATIAL MEMORY; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

ALLOSTERIC REGULATION; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, METABOTROPIC GLUTAMATE; SMALL MOLECULE LIBRARIES;

EID: 67649992440     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. W: mGluR5 antagonists: Discovery, characterization and drug development. Curr Opin Drug Discovery Dev (2008) 11(5): 655-665.
2. Jaeschke G, Wettstein JG, Nordquist RE, Spooren W: mGlu5 receptor antagonists and their therapeutic potential.Expert Opin Ther Patents (2008) 18(2):123-142.
3. Rodriguez AL, Williams R: Recent progress in the development of allosteric modulators of mGluR5. Curr Opin Drug Discovery Dev (2007) 10(6):715-722.
4. Bach P, Isaac M, Slassi A: Metabotropic glutamate receptor 5 modulators and their therapeutic applications. Expert Opin Ther Patents (2007) 17(4):371-384.
5. Schoepp DD, Jane DE, Monn JA: Pharmacological agents acting at subtypes of metabotropic glutamate receptors.Neuropharmacology (1999) 38(10):1431-1476. · Provides a historical perspective of the evolution of the mGluR field as a therapeutic target.
6. Conn PJ, Pin J-P: Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol (1997) 37:205- 237. · Thoroughly discusses the pharmacology, function and therapeutic potential of the mGluRs.
7. Ritzén A, Mathiesen JM, Thomsen C: Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol (2005) 97(4):202-213.
8. Kew JN: Positive and negative allosteric modulation of metabotropic glutamate receptors: Emerging therapeutic potential. Pharmacol Ther (2004) 104(3):233-244.
9. Gasparini F, Lingenhöhl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA et al: 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systematically active mGlu5 receptor antagonist. Neuropharmacology (1999) 38(10):1493-1503. ·· Details the early in vitro and in vivo pharmacological characterization of MPEP.
10. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L, Brodkin J, Jiang X, McDonald I, Rao S et al: 3-[(2-Methyl- 1,3-thiazol-4-yl)ethynyl]-pyridine: A potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem (2003) 46(2):204-206.
11. Herzig V, Schmidt WJ: Effects of MPEP on locomotion, sensitization and conditioned reward induced by cocaine or morphine. Neuropharmacology (2004) 47(7):973-984.
12. Hodge CW, Miles MF, Sharko AC, Stevenson RA, Hillmann JR, Lepoutre V, Besheer J, Schroeder JP: The mGluR5 antagonist MPEP selectively inhibits the onset and maintenance of ethanol self-administration in C57BL/6J mice.Psychopharmacology (2006) 183(4):429-438.
13. Zhu CZ, Wilson SG, Mikusa JP, Wismer CT, Gauvin DM, Lynch JJ 3rd, Wade CL, Decker MW, Honore P: Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol (2004) 506(2):107-118.
14. Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Wisłowska A, Płaźnik A, Bespalov AY, Danysz W: Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats.Eur J Pharmacol (2005) 514(1):25-34.
15. Busse CS, Brodkin J, Tattersall D, Anderson JJ, Warren N, Tehrani L, Bristow LJ, Varney MA, Cosford ND: The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology (2004) 29(11):1971-1979.
16. Klodzinska A, TatarczyŃska E, Chojnacka-Wójcik E, Nowak G, Cosford ND, Pilc A: Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABAA signaling. Neuropharmacol (2004) 47(3):342-350.
17. Spooren WPJM, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, Porsolt RD, Gentsch C: Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6- (phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther (2000) 295(3):1267-1275.
18. Jensen J, Lehmann A, Uvebrant A, Carlsson A, Jerndal G, Nilsson K, Frisby C, Blackshaw LA, Mattsson JP: Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur J Pharmacol (2005) 519(1-2):154-157.
19. Frisby CL, Mattsson JP, Jensen JM, Lehmann A, Dent J, Blackshaw LA: Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology(2005) 129(3):995-1004.
20. de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, Oostra BA, Willemsen R: Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis (2008) 31(1):127-132.
21. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP: Suppression of two major fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacol (2005) 49(7): 1053-1066.
22. Leonibus ED, Managò F, Giordani F, Petrosino F, Lopez S, Oliverio A, Amalric M, Mele A: Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease. Neuropsychopharmacology (2009) 34(3):729-738.
23. Bisaga A, Danysz W, Foltin RW: Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder.Eur Neuropsychopharmacol (2008) 18(11):794-802.
24. Movsesyan VA, O'Leary DM, Fan L, Bao W, Mullins PG, Knoblach SM, Faden AI: mGluR5 antagonists 2-methyl-6-(phenylethynyl)- pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl d-aspartate receptors. J Pharmacol Exp Ther (2001) 296(1):41-47.
25. Mathiesen JM, Svendsen N, Bräuner-Osborne H, Thomsen C, Ramirez MT: Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol (2003) 138(6):1026-1030.
26. King CD: Inhibition of human hepatic CYP isoforms by mGluR5 antagonists. Life Sci 75(8):947-953.
27. Green MD, Yang X, Cramer M, King CD: In vitro metabolic studies on the selective metabotropic glutamate receptor sub-type 5 (mGluR5) antagonist 3-[(2-methyl-1,3-thiazol-4- yl)ethynyl]-pyridine (MTEP). Neurosci Lett (2006) 391(3):91-95.
28. Carroll FI, Kotturi SV, Navarro HA, Mascarella SW, Gilmour BP, Smith FL, Gabra BH, Dewey WL: Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl) pyridine. J Med Chem(2007) 50(14):3388-3391.
29. Iso Y, Grajkowska E, Wroblewski JT, Davis J, Goeders NE, Johnson KM, Sanker S, Roth BL, Tueckmantel W, Kozikowski AP: Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications.J Med Chem (2006) 49(3):1080-1110.
30. Micheli F, Bertani B, Bozzoli A, Crippa L, Cavanni P, Di Fabio R, Donati D, Marzorati P, Merlo G, Paio A, Perugini L et al: Phenylethynylpyrrolo[ 1,2-a]pyrazine: A new potent and selective tool in the mGluR5 antagonist arena. Bioorg Med Chem Lett (2008) 18(6):1804-1809.
31. Sharma S, Rodriguez AL, Conn PJ, Lindsley CW: Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold.Bioorg Med Chem Lett (2008) 18(14):4098-4101. ·· Describes a 'molecular switch' that affords both negative and positive allosteric modulators of mGluR5 within the same chemical series.
32. Rodriguez AL, Nong Y, Sekaran NK, Alagille D, Tamagnan GD, Conn PJ: A close structural analog of 2-methyl-6- (phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators.Mol Pharmacol (2005) 68(6):1793-1802. · Describes the pharmacology of a neutral allosteric ligand of mGluR5 and two partial antagonists that bind at the same allosteric site.
33. Kulkarni SS, Nightingale B, Dersch CM, Rothman RB, Newman AH: Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett(2006) 16(13):3371-3375.
34. Kulkarni SS, Newman AH: Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett (2007) 17(7):2074- 2079.
35. Bonnefous C, Vernier J-M, Hutchinson JH, Chung J, Reyes-Manalo G, Kamenecka T: Dipyridyl amides: Potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.Bioorg Med Chem Lett (2005) 15(4):1197-1200.
36. Kamenecka TM, Bonnefous C, Govek S, Vernier J-M, Hutchinson J, Chung J, Reyes-Manalo G, Anderson JJ: Dipyridyl amines: Potent metabotropic glutamate subtype 5 receptor antagonists. Bioorg Med Chem Lett (2005) 15(19):4350-4353.
37. Kulkarni SS, Newman AH: Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett (2007) 17(11):2987-2991.
38. Milbank JB, Knauer CS, Augelli-Szafran CE, Sakkab-Tan AT, Lin KK, Yamagata K, Hoffman JK, Zhuang N, Thomas J, Galatsis P, Wendt JA et al: Rational design of 7-arylquinolines as noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett (2007) 17(16):4415-4418. ·· Describes the discovery of an mGluR5 NAM from a chemotype other than MPEP with activity in a rodent anxiety model when administered orally.
39. Vogel JR, Beer B, Clody DE: A simple and reliable conflict procedure for testing anti-anxiety. Psychopharmacologia (1971) 21(1):1-7.
40. Wendt JA, Deeter SD, Bove SE, Knauer CS, Brooker RM, Augelli-Szafran CE, Schwarz RD, Kinsora JJ, Kilgore KS: Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett (2007) 17(19): 5396-5399. ·· Describes the discovery of an mGluR5 NAM from a chemotype other than MPEP with activity in a rodent model of OA pain when administered orally.
41. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, Schrier DJ, Kilgore KS: Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage (2003) 11(11):821-830.
42. Galatsis P, Yamagata K, Wendt JA, Connolly CJ, Mickelson JW, Milbank JB, Bove SE, Knauer CS, Brooker RM, Augelli-Szafran CE, Schwarz RD et al: Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett (2007) 17(23):6525-6528.
43. Rodriguez AL, Williams R, Zhou Y, Lindsley SR, Le U, Grier MD, Weaver D, Conn PJ, Lindsley CW: Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. Bioorg Med Chem Lett (2009) 19(12):3209-3213. ·· Describes the first example in a chemical series not based on MPEP of a 'molecular switch' capable of producing both positive and negative allosteric modulators of mGluR5.
44. Addex Pharmaceuticals Inc: Addex announces ADX10059 phase IIa acute anxiety data. Press Release (2008) January 03.
45. Addex Pharmaceuticals Inc: Addex: Better tolerated formulation of ADX10059 reduces acid reflux. Press Release (2008) September 10. · Describes clinical data providing further validation of mGluR5 NAMs as a potential treatment for GERD in humans.
46. Addex Pharmaceuticals Inc: Addex starts phase IIb ADX10059, proton pump inhibitor combination study in GERD patients.Press Release (2008) December 02.
47. Addex Pharmaceuticals Inc: Addex starts a second phase IIb trial of ADX10059 in GERD. Press Release (2008) December 17.
48. Addex Pharmaceuticals Inc: Addex starts a phase IIb trial of ADX10059 for migraine prevention. Press Release (2008) December 17.
49. FRAXA Research Foundation: First fenobam trial results are positive. Press Release (2008) July 22.
50. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, Allan T: Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study.J Clin Psychopharmacol (1982) 2(2):129-132.
51. Porter RH, Jaeschke G, Spooren W, Ballard TM, Büttelmann B, Kolczewski S, Peters JU, Prinssen E, Wichmann J, Vieira E, Mühlemann A et al: Fenobam: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther (2005) 315(2):711-721.
52. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchison J, Snape M, Tranfaglia M, Nguyen DV, Hagerman R: A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet (2009) 46(4):266-271. ·· Details the first clinical study of the safety and pharmacokinetics of an mGluR5 antagonist in humans with fragile X syndrome.
53. Neuropharm Group plc: Edison investment research review.Research Notes (2009): March 18.
54. Novartis AG (Glatthar R, Carcache D, Spanka C, Vranesic I-T, Troxler TJ): Novel bi-aryl amines. WO-2007113276 (2007).
55. Novartis AG (Glatthar R, Orain D, Spanka C): Nicotinic acid derivatives as modulators of metabotropic glutamate receptors. WO-2007071358 (2007).
56. Merz Pharma GMBH & Co (Danysz W, Dekundy A, Hechenberger M, Henrich M, Jatzke C, Nagel J, Parsons CGR, Weil T, Fotins J, Gutcaits A, Kalvinsh I et al): Pyrazolopyrimidines, a process for their preparation and the use as a medicine. WO-2008015271 (2008).